Staxyn was a prescription brand of vardenafil formulated as a 10 mg orally disintegrating tablet (ODT) for erectile dysfunction. The original branded U.S. presentation was discontinued, but historic Staxyn labeling remains important because it explains the specific characteristics of the dissolving formulation. Its brand name should not be interpreted as a currently marketed branded purchase offer.
A key labeling warning is that Staxyn 10 mg ODT was not interchangeable with a 10 mg film-coated Levitra tablet. The orally disintegrating form produces greater systemic exposure and uses formulation-specific handling and prescribing instructions. Modern generic vardenafil ODT applications must be evaluated separately from both historical brands.
This page explains Staxyn’s brand history and the distinction from ordinary tablets. Readers seeking current generic dissolving-product information should use the vardenafil ODT guide; those seeking conventional generic tablets can use the generic vardenafil guide.
Historical U.S. Staxyn labeling identified vardenafil hydrochloride and a 10 mg orally disintegrating tablet for as-needed ED treatment. The medicine was intended to dissolve on the tongue, not to be swallowed as an ordinary film-coated tablet with the expectation of identical exposure.
The brand was a specific dosage form, not a general nickname for all generic vardenafil products. A search result that omits the words orally disintegrating can lead to clinically important confusion when a person compares old and new prescriptions.
When the original branded Staxyn presentation stopped being marketed in the United States, the vardenafil ODT formulation category did not necessarily disappear. FDA-approved generic ODT products have separate applications and labels that can be researched on their own merits.
Approval records and current dispensing inventory are different. Do not treat an old brand advertisement as a live offer; ask the pharmacist to identify the exact generic product and verify whether it can be lawfully dispensed.
Staxyn labeling explicitly described higher systemic vardenafil exposure compared with 10 mg film-coated Levitra tablets. Thus, matching the active ingredient and nominal 10 mg strength is insufficient to establish interchangeability. It is a formulation-specific pharmacokinetic issue, not a matter of packaging preference.
The prescriber must determine the appropriate form; a patient should not swap the two or combine them. The conventional 10 mg tablet page covers the film-coated product specifically, not the ODT.
The information below explains what belonged to the original brand and what must be checked independently today. It is not a substitution chart or current inventory report.
A pharmacist can confirm the appropriate FDA-approved generic form and the original directions on the prescription.
| Attribute | Historical Staxyn ODT | Film-coated vardenafil |
|---|---|---|
| Brand context | Discontinued 10 mg Staxyn brand | Discontinued Levitra brand; generics separately approved |
| Form | Orally disintegrating tablet | Conventional film-coated tablet |
| Exposure | Higher exposure than 10 mg film-coated reference | Different pharmacokinetic profile |
| Administration | Dissolve on tongue as labeled | Swallow according to product directions |
| Interchangeability | Not automatically interchangeable | Requires correct prescription form |
| Current market | Verify independently approved generic ODT | Verify generic film-coated stock |
The historical instructions described placing the tablet on the tongue to disintegrate, with specific guidance about use without liquid and removing it from its blister immediately before use. Those directions should not be generalized to all oral products or substituted for the label of a currently dispensed generic.
If a person receives an approved generic ODT, review its own current patient information and the pharmacist’s instructions. A historical package insert provides context but does not override a present-day prescription.
The historical Staxyn 10 mg ODT contained aspartame, corresponding to 1.01 mg phenylalanine per tablet, relevant to people with phenylketonuria. It also contained sorbitol: the historical labeling said people with rare hereditary fructose intolerance should not take Staxyn. These are product-specific excipient facts, not assumptions about the composition of every current generic ODT; the dispensing pharmacist must check the exact label.
Historical Staxyn labeling instructed against use in moderate or severe hepatic impairment, in patients receiving renal dialysis, and with moderate or potent CYP3A4 inhibitors. It also instructed clinicians not to initiate treatment with Staxyn in patients taking alpha-blockers. These restrictions make the formulation meaningfully different from choosing a conventional tablet strength and require clinician review of the current product label.
Vardenafil products must not be used with nitrate medicines or riociguat. Historical Staxyn labeling also warned about QT prolongation, congenital long-QT syndrome and class IA or III antiarrhythmic medicines. Unlike a vague caution about drug metabolism, it instructed against concomitant use with moderate or potent CYP3A4 inhibitors. The ODT dosage form does not bypass these risks.
Any prolonged erection exceeding four hours requires emergency evaluation; sudden vision or hearing changes require prompt medical attention. See the vardenafil interaction overview for the broader medicine list.
A pharmacy search page may retain a Staxyn entry because the brand is a reference for an approved generic ODT. That does not mean branded Staxyn is being filled. Some results may also conflate the ODT with conventional tablets, so inspect the labeled dosage form and application details carefully.
Be cautious of websites offering a historical brand without prescription validation or proof of state pharmacy licensure. The online-pharmacy guide explains how to verify a legitimate U.S. seller.
Ask the licensed pharmacy to identify the exact approved ODT application, strength, pack and current supply. If the pharmacy has only film-coated tablets, the pharmacist should consult the prescriber rather than silently replace an ODT prescription.
A current listing is not a promise of availability. The availability guide addresses how to verify real pharmacy supply without mistaking FDA approval for an inventory report.
Bring the old prescription details or a reliable medicine record to the clinician. Explain which formulation was used, how it was tolerated and which other medicines are being taken now. Ask whether a current FDA-approved ODT is appropriate or whether a different prescribed treatment plan is preferable.
For a general discussion of product identity and lawful dispensing, use the vardenafil hub and the U.S. prescription pharmacy guide. The decision should be clinical, not based on an old brand name.
Staxyn was the former U.S. brand for a 10 mg orally disintegrating vardenafil tablet used for erectile dysfunction.
The original U.S. branded presentation was discontinued; generic ODT products have separate approval records.
No. The ODT formulation had higher systemic exposure and was specifically labeled as not interchangeable with 10 mg film-coated Levitra.
FDA-approved generic ODT product records exist, but the precise application and current pharmacy supply should be verified.
Historical labeling described placing the tablet on the tongue to dissolve, following special directions about blister removal and liquids.
Yes. The historical Staxyn ODT label specified 1.01 mg phenylalanine per tablet from aspartame. It also listed sorbitol and warned against use in rare hereditary fructose intolerance. Verify excipients separately for any currently dispensed generic.
Do not make that substitution independently. A clinician and pharmacist must review the different formulation and prescription.
No. Vardenafil remains subject to nitrate, blood-pressure and QT-related restrictions. Historical Staxyn labeling also instructed against use with certain CYP3A4 inhibitors and in some hepatic or renal conditions.